Bifogade filer
Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, announces that the acquisition of all shares in CyberGene AB (“CyberGene”) that was announced on 11 February 2026 has today been completed and that closing has occurred. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. In connection with closing, Devyser has carried out an issue of compensation shares to the seller Level Bio AB (publ).
CyberGene develops and markets products in the fields of aneuploidy and male infertility, complementing Devyser’s existing product portfolio. The total purchase consideration amounts to appx. SEK 12.2 million and has been paid through newly issued shares in Devyser.
Devyser, through its wholly-owned subsidiary Devyser AB, on 11 February 2026 entered into a share purchase agreement with Level Bio AB (publ) relating to the acquisition of all shares in CyberGene. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled and closing has today, 1 April 2026, been completed.
Cybergene was founded in 1995 and has demonstrated steady growth driven by a strong product offering and consistent market expansion. Devyser and Cybergene have been active in similar markets for many years, providing Devyser with in-depth knowledge of Cybergene’s products and their strong customer acceptance.
The acquisition is consolidated from and including 1 April 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.
As previously announced, the acquisition is fully financed through a directed issue of new shares in Devyser to Level Bio AB (publ), to be paid by way of set-off against the seller’s claim on the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors today resolved upon an issue of 124,363 new shares in Devyser, entitling Level Bio AB (publ), as the seller of CyberGene, to subscribe for the new shares. The subscription price corresponds to the volume-weighted average price (VWAP) of the Devyser share on Nasdaq First North Premier Growth Market during the ten (10) trading days following and including 11 February 2026 and amounts to approximately SEK 98.29 per share. Level Bio AB (publ) has subscribed for all 124,363 shares and the share issue corresponds to a dilution of approximately 0.74 per cent of all shares and votes in Devyser. Following the share issue, the total share capital in Devyser amounts to approximately SEK 963,497.29 and the total number of shares and votes amounts to 16,788,555.